Stimulated mast cells release inflammatory cytokines: Potential suppression and therapeutical aspects

Journal of Biological Regulators and Homeostatic Agents

Volumn 32, Issue 6, 2018, Pages 1355-1360

  Varvara, G ^a   Tettamanti, L ^b   Gallenga, C E ^c   Caraffa, Al ^d   D'Ovidio C ^a   Mastrangelo, F ^e   Ronconi, G ^f   Kritas, S K ^g   Conti, Pio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cytokines; Inflammation; Mast cells

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 33; INTERLEUKIN 37; TUMOR NECROSIS FACTOR; IL33 PROTEIN, HUMAN; IL37 PROTEIN, HUMAN; IMMUNOGLOBULIN E RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CYTOKINE RELEASE; EDITORIAL; HUMAN; INFLAMMATION; INNATE IMMUNITY; MAST CELL; PROTEIN EXPRESSION; PSORIASIS; RHEUMATOID ARTHRITIS; ADAPTIVE IMMUNITY; IMMUNOLOGY;

ADAPTIVE IMMUNITY; CYTOKINES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-33; MAST CELLS; RECEPTORS, IGE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85058875182     PISSN: 0393974X     EISSN: 17246083     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells:recent advances. Annu Rev Immunol 2005; 23:749-86. Review.
2. Theoharides TC, Stewart JM, Taracanova A, Conti P, Zouboulis CC. Neuroendocrinology of the skin. Rev Endocr Metab Disord 2016; 17(3):287-94. Review.
3. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354(1):24-31.
4. Conti P, Caraffa A, Ronconi G, et al. Mast cells participate in allograft rejection: can IL-37 play an inhibitory role? Inflamm Res 2018;6 7(9):747-55.
5. Conti P, Caraffa A, Mastrangelo F, et al. Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37. Cell Prolif 2018; 51(5):e12475.
6. Conti P, Caraffa A, Ronconi G, Kritas SK, Mastrangelo F, Tettamanti L, Theoharides TC. Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. Eur J Pharmacol 2018;818:294-99.
7. Conti P, Carinci F, Lessiani G, et al. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Immunol Res 2017; 65(5):982-86.
8. Dinarello CA. Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. Immunol Rev 2018; 281(1):5-7.
9. Tettamanti L, Kritas SK, Gallenga CE, et al. IL-33 mediates allergy through mast cell activation:Potential inhibitory effect of certain cytokines. J Biol Regul Homeost Agents 2018; 32(5):1061-65.
10. Caraffa A, Conti C, D’Ovidio C, et al. New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators. J Biol Regul Homeost Agents 2018; 32(3):449-54. Review.
11. Dinarello CA, Conti P, Mier JW. Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? Yale J Biol Med 1986; 59(2):97-106.
12. Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A 2018; 115(40):E9381-90.
13. Mastrangelo F, Frydas I, Ronconi G, et al. Lowgrade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37. J Biol Regul Homeost Agents 2018; 32(2):195-98.
14. Taracanova A, Alevizos M, Karagkouni A, et al. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci U S A 2017; 114(20):E4002-E4009. doi: 10.1073/ pnas.1524845114.
15. Conti P, Lessiani G, Kritas SK, Ronconi G, Caraffa A, Theoharides TC. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Tissue Cell 2017; 49(3):393-400.
16. Sibilano R, Gaudenzio N, DeGorter MK, et al. A TNFRSF14-FcɛRI-mast cell pathway contributes to development of multiple features of asthma pathology in mice. Nat Commun 2016; 7:13696. doi:10.1038/ncomms13696.
17. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev 2018; 282(1):121-50.
18. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 2018; 281(1):8-27. doi: 10.1111/imr.12621. Review.
19. Theoharides TC, Leeman SE. Effect of IL-33 on de novo synthesized mediators from human mast cells. J Allergy Clin Immunol 2018. doi: 10.1016/j. jaci.2018.09.014.
20. Dinarello CA, Kaplanski G. Indeed, IL-18 is more than an inducer of IFN-γ. J Leukoc Biol 2018; 104(2):237-38.
21. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 2018; 281(1):179-90.
22. Kritas SK, Gallenga CE, D Ovidio C, et al. Impact of mold on mast cell-cytokine immune response. J Biol Regul Homeost Agents 2018; 32(4):763-68.
23. Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, Gleason RM, Russell IJ. Fibromyalgia syndrome in need of effective treatments. J Pharmacol Exp Ther 2015; 355(2):255-63.
24. Hatziagelaki E, Adamaki M, Tsilioni I, Dimitriadis G, Theoharides TC. Myalgic encephalomyelitis/ chronic fatigue syndrome-metabolic disease or disturbed homeostasis due to focal inflammation in the hypothalamus? J Pharmacol Exp Ther 2018; 367(1):155-67.
25. Conti P, Ronconi G, Kritas SK, Caraffa A, Theoharides TC. Activated mast cells mediate lowgrade inflammation in Type 2 diabetes: Interleukin-37 could be beneficial. Can J Diabetes 2018; 42(5):568-73.
26. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC. Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 2016; 356(3):664-72.